中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 9
Sep.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(9): 2096-2102

Influencing factors for compliance with hepatocellular carcinoma surveillance in patients with chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2023.09.010
  • 1.

    College of Clinical Chinese Medicine，Hubei University of Chinese Medicine，Wuhan 430065，China

  • 2.

    Hubei Key Laboratory of Theoretical and Applied Research of Liver and Kidney in Traditional Chinese Medicine，Department of Hepatology，Hubei Provincial Hospital of Traditional Chinese Medicine，Wuhan 430061，China

  • 3.

    Hubei Academy of Chinese Medicine，Wuhan 430074，China

Research funding:

Thirteenth Five－Year National Science and Technology Major Project (2018ZX10302204);

Public Health Leading Talents Training Program of Hubei Province (E weitong ［2021］ No. 73)

More Information
  • Corresponding author: LI Xiaodong， lixiaodong555@126.com （ORCID： 0000－0002－6406－9416）
  • Received Date: 2022-12-29
  • Accepted Date: 2023-02-15
  • Published Date: 2023-09-19
    Abstract
  •   Objective  To investigate the influencing factors for compliance with hepatocellular carcinoma （HCC） surveillance in patients with chronic hepatitis B （CHB）.  Methods  The CHB patients who participated in the clinical study of Hubei Provincial Hospital of Traditional Chinese Medicine from June 2012 to December 2016 and had an interval of >4 years from the end of the clinical study were enrolled， and a questionnaire follow－up survey was conducted from September 2020 to December 2021. Early screening for HCC was conducted at least every 6 months as regular surveillance， and compliance with 4－year regular surveillance and related influencing factors were analyzed in the population at a high risk of HCC. The Wilcoxon rank－sum test was used for comparison of non－normally distributed continuous data between two groups， and the chi－square test was used for comparison of categorical data between groups. A multivariate Logistic regression analysis was used to investigate the influencing factors for regular HCC surveillance in CHB patients.  Results  A total of 223 CHB patients were enrolled， and 30.94% （69/223） of these CHB patients underwent regular HCC surveillance. The univariate analysis showed that age （χ2＝11.940， P＝0.003）， long－term health education （χ2＝32.066， P<0.001）， use of antiviral drugs （χ2＝10.004， P＝0.002）， and HBV DNA （χ2＝12.365， P<0.001） were associated with the compliance with regular HCC surveillance in patients. The multivariate Logistic regression analysis showed that age ≥60 years （odds ratio ［OR］＝0.197， 95% confidence interval ［CI］： 0.050－0.777， P＝0.020） and long－term health education （OR＝4.810， 95% CI： 2.219－10.429， P<0.001） were independent influencing factors for compliance with HCC surveillance in CHB patients.  Conclusion  There is poor overall compliance with regular HCC surveillance in CHB patients. CHB patients aged ≥60 years had poorer compliance with regular HCC surveillance than the other age groups， and patients receiving long－term health education tend to have good compliance with regular HCC surveillance.

     

    • FullText(HTML)
  • loading
    • References(19)
  • [1]
    SUNG H, FERLAY J, SIEGEL RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71( 3): 209－ 249. DOI: 10.3322/caac.21660.
    [2]
    LLOVET JM, KELLEY RK, VILLANUEVA A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7( 1): 6. DOI: 10.1038/s41572－020－00240－3.
    [3]
    ZHENG RS, ZHANG SW, ZENG HM, et al. Cancer incidence and mortality in China, 2016[J]. J Nat Cancer Cent, 2022, 2( 1): 1－ 9.
    [4]
    de MARTEL C, GEORGES D, BRAY F, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis[J]. Lancet Glob Health, 2020, 8( 2): e180－e190. DOI: 10.1016/S2214－109X(19)30488－7.
    [5]
    YANG SL, LUO YY, CHEN M, et al. A systematic review and meta－analysis comparing the prognosis of multicentric occurrence and vs. intrahepatic metastasis in patients with recurrent hepatocellular carcinoma after hepatectomy[J]. HPB(Oxford), 2017, 19( 10): 835－ 842. DOI: 10.1016/j.hpb.2017.06.002.
    [6]
    TSILIMIGRAS DI, BAGANTE F, SAHARA K, et al. Prognosis after resection of Barcelona Clinic Liver Cancer(BCLC) stage 0, A, and B hepatocellular carcinoma: A comprehensive assessment of the current BCLC classification[J]. Ann Surg Oncol, 2019, 26( 11): 3693－ 3700. DOI: 10.1245/s10434－019－07580－9.
    [7]
    General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer(2022 edition)[J]. J Clin Hepatol, 2022, 38( 2): 288－ 303. DOI: 10.3969/j.issn.1001－5256.2022.02.009.

    国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 2): 288－ 303. DOI: 10.3969/j.issn.1001－5256.2022.02.009.
    [8]
    GUO LW, ZHANG SK, LIU SZ, et al. Compliance rate and impact factor analysis of liver cancer screening in urban areas of Henan Province[J]. Chin J Oncol, 2021, 43( 2): 233－ 237. DOI: 10.3760/cma.j.cn112152－20200331－00286.

    郭兰伟, 张韶凯, 刘曙正, 等. 河南省城市地区肝癌筛查依从性及其影响因素分析[J]. 中华肿瘤杂志, 2021, 43( 2): 233－ 237. DOI: 10.3760/cma.j.cn112152－20200331－00286.
    [9]
    MA YL, QIAN LT, WEI DH, et al. The compliance of liver cancer screening and related influencing factors in Hefei City of Anhui Province from 2014 to 2017[J]. China Cancer, 2021, 30( 12): 895－ 900. DOI: 10.11735/j.issn.1004－0242.2021.12.A003.

    马艳玲, 钱立庭, 魏东华, 等. 2014－2017年安徽省合肥市城市肝癌高危人群筛查依从性及其相关影响因素分析[J]. 中国肿瘤, 2021, 30( 12): 895－ 900. DOI: 10.11735/j.issn.1004－0242.2021.12.A003.
    [10]
    Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019, 35( 12): 2648－ 2669. DOI: 10.3969/j.issn.1001－5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 12): 2648－ 2669. DOI: 10.3969/j.issn.1001－5256.2019.12.007.
    [11]
    ZHENG XY. Guiding principles for clinical research of new traditional Chinese medicine(Trial)[M]. Beijing: China Medical Science Press, 2002.

    郑筱萸. 中药新药临床研究指导原则(试行)[M]. 北京: 中国医药科技出版社, 2002.
    [12]
    SHIM JJ, KIM GA, OH CH, et al. Reduced liver cancer mortality with regular clinic follow－up among patients with chronic hepatitis B: A nationwide cohort study[J]. Cancer Med, 2020, 9( 20): 7781－ 7791. DOI: 10.1002/cam4.3421.
    [13]
    LIU C, DAI JY, ZHAO J. Changes in adherence to hepatocellular carcinoma surveillance among high－risk population in a hospital in Yunnan and the related influencing factors[J]. Chin Prev Med, 2023, 24( 2): 122－ 128. DOI: 10.16506/j.1009－6639.2023.02.006.

    刘畅, 戴静毅, 赵军. 2018—2019年云南省某医院肝癌高危人群肝癌监测依从性变化及影响因素分析[J]. 中国预防医学杂志, 2023, 24( 2): 122－ 128. DOI: 10.16506/j.1009－6639.2023.02.006.
    [14]
    ZHANG BH, YANG BH, TANG ZY. Randomized controlled trial of screening for hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2004, 130( 7): 417－ 422. DOI: 10.1007/s00432－004－0552－0.
    [15]
    MARRERO JA, KULIK LM, SIRLIN CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 68( 2): 723－ 750. DOI: 10.1002/hep.29913.
    [16]
    HOU JL, ZHAO W, LEE C, et al. Outcomes of long－term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries[J]. Clin Gastroenterol Hepatol, 2020, 18( 2): 457－ 467. DOI: 10.1016/j.cgh.2019.07.010.
    [17]
    CHEEWAKRIANGKRAI C, KIETPEERAKOOL C, CHAROENKWAN K, et al. Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer[J]. Cochrane Database Syst Rev, 2020, 3( 3): CD013253. DOI: 10.1002/14651858.CD013253.pub2.
    [18]
    MUSA J, ACHENBACH CJ, O'DWYER LC, et al. Effect of cervical cancer education and provider recommendation for screening on screening rates: A systematic review and meta－analysis[J]. PLoS One, 2017, 12( 9): e0183924. DOI: 10.1371/journal.pone.0183924.
    [19]
    ZHU CH, WU YK, LI XY, et al. The compliance and its affecting factors with treatment guideline recommendations of chronic HBV infection: A long－term follow－up cohort study[J]. Guangdong Med J, 2016, 37( 23): 3578－ 3582. DOI: 10.3969/j.issn.1001－9448.2016.23.030.

    朱昌浩, 吴元凯, 李向永, 等. 慢性HBV感染者长期随访队列患者依从性现状及其影响因素[J]. 广东医学, 2016, 37( 23): 3578－ 3582. DOI: 10.3969/j.issn.1001－9448.2016.23.030.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (179) PDF downloads(28) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return